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Familial hypercholesterolaemia (FH) is a hereditary autosomal dominant disorder with impaired function of LDL-C receptors, resulting in insufficient cellular binding and clearance of plasma LDL-C, and a lifelong elevated LDL-C levels. 2 If left untreated, patients with FH have a 13-fold higher risk for coronary artery disease, and if treated with standard lipid-lowering medications (i.e. statins, ezetimibe) then a 10-fold higher risk. 3 This emphasises the limitations of conventional lipid-lowering treatment in those patients.
In addition to having increased levels of LDL-C, patients with FH also have an increased level of lipoprotein (a) (Lp(a)), comprising of LDL core and apolipoprotein (a). 4 Increased levels of Lp(a) have strong proatherogenic and prothrombotic properties. 5 Lp(a) is a risk factor for major coronary events. 6 In patients with FH, increased levels of Lp(a) confer a five-fold higher risk of myocardial infarction. 4 Standard lipid-lowering therapy has failed to significantly reduce Lp(a), but proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and nicotinic acid can decrease this lipid fraction by 25.5-36%. [7] [8] [9] Lipoprotein apheresis enables extracorporeal removal of both LDL-C and Lp(a). 10 In patients with increased Lp(a), this procedure significantly reduced the incidence of adverse cardiovascular events by 74%. 11 Likewise, lipoprotein apheresis can have an impact on the reduction of LDL-C plasma levels of up to 80%. 12 However, the beneficial effects of lipoprotein apheresis last only temporarily, and a rapid rebound is seen in the next few days, reaching a plateau during the second week. 13 Consequently, a steady state of improved lipoprotein profile can be obtained only by repetitive apheresis at regular intervals, with concomitant diet and pharmacological treatment. 12, 13 Recent European Society of Cardiology (ESC) guidelines on the management of dyslipidaemias support lipoprotein apheresis for patients with homozygous FH, in whom pharmacological treatment demonstrated limited effectiveness.
14 In some European countries, lipoprotein apheresis is approved for heterozygous FH and severe nonhereditary hypercholesterolaemia in the case of intolerance or refractoriness to standard lipid-lowering drugs. 12 In spite of a clear beneficial effect, certain limitations of apheresis should be stressed: invasive venous approach, hypotensive reactions, potential interaction with angiotensin-converting-enzyme (ACE) inhibitors, need for repetitive procedures and cost. 12 Considering these drawbacks, lipoprotein apheresis is not a convenient long-term strategy for the management of patients with FH. There has been a growing interest in establishing an adjuvant treatment capable of maintaining or even improving the lipid profile achieved by apheresis. The combined effect of apheresis and the adjuvant treatment would have a sustained impact on the reduction of cardiometabolic risk in patients with FH.
PCSK9 is a protease synthetised in liver; it binds to LDL receptors and enables their degradation by lysosomes, resulting in an increase of LDL-C concentration. 15, 16 In FH, there are also high levels of PCSK9 due to the lack of LDL receptors, and PCSK9 positively correlates with LDL-C levels. 17 Monoclonal antibodies targeting PCSK9 (i.e. PCSK9 inhibitors) have a proven benefit for the management of FH. significant decrease in LDL-C levels and lower rates of all-cause mortality and myocardial infarction in adults using PCSK9 inhibitors.
19 PCSK9 inhibitors could also reduce the need for lipoprotein apheresis in patients with heterozygous or polygenetic FH. 10, 20 This was suggested by a double-blind randomised study of alirocumab, showing a reduction in the rate of apheresis treatments by 75% compared to placebo. 21 The observational study by Zenti et al. presented in the November issue of the European Journal of Preventive Cardiology, investigated the efficacy of a treatment comprised of switching from apheresis to PCSK9 inhibitors. 22 The study group included nine patients with FH and cardiovascular disease. The endpoint was the effect of treatment on lipid profile and inflammatory markers. The investigated PCKS9 inhibitors were evolocumab or alirocumab. 22 Lipid levels and inflammatory biomarkers were compared before and after 12 months of apheresis, as well as before and after switching to six months of PCSK9 inhibitor treatment. The study showed that after apheresis, total cholesterol (TC) and LDL-C levels were reduced by 53.9% and 64.0%, respectively. Furthermore, both triglycerides (TGs) and Lp(a) levels were significantly decreased by apheresis. However, this treatment also resulted in 16% reduction in high-density lipoprotein cholesterol (HDL-C), which might have a negative impact on cardiometabolic risk. 23, 24 After switching all nine patients to the six-month treatment with PCSK9 inhibitors (in combination with statin/ezetimibe), lipoproteins were compared to the pre-apheresis levels. PCSK9 inhibition resulted in a reduction of TC and LDL-C to a similar extent as apheresis (by 46.5% and 74.1%, respectively). Unlike apheresis, PCSK9 inhibition provided an increase in plasma HDL-C levels by 34.0%. The effect on LDL-C levels was observed after one month of PCSK9 treatment and was maintained throughout the study, while there was a rebound following apheresis. However, PCSK9 inhibitors were less effective in reducing TG compared with apheresis. On average, Lp(a) was significantly reduced with PCSK9 inhibitor therapy (by 56%), except in patients with highly increased levels of Lp(a). Apheresis also significantly reduced highsensitivity C-reactive protein (hsCRP) concentration by 60.8%, however PCSK9 inhibitors demonstrated no influence on hsCRP levels. In addition, neither lipoprotein apheresis nor PCSK9 inhibition had any effect on interleukin (IL)-6 levels. 22 Since the present study has a small sample size, it should be viewed as hypothesis-generating. In addition, the patients were older and prevalently male. There may be hidden confounders, such as genetic variants, initial lipid status, previous treatment and comorbidities. Study strength would be increased if a randomised cross-over design and cardiovascular endpoints were adopted. The advantages of the study should be stressed including the long-term trial duration and highly standardised protocol for sample collection and analyses. Patients received statin therapy which might have influenced levels of the inflammatory biomarkers and it would be good to know the results in statin-naive patients.
In addition to improving the serum lipid profile, lipoprotein apheresis has a number of pleiotropic effects that might have a beneficial role for reducing the risk of atherothrombosis. 25, 26 Lipoprotein apheresis can decrease hsCRP, as well as several other biomarkers associated with plaque destabilization and rupture. 27 Moreover, this treatment could improve endothelial function by positively affecting circulating endothelial and progenitor cells and flow-mediated vasodilatation. 25 Lipoprotein apheresis also downregulates the expression of key pro-inflammatory cytokines, including hsCRP, IL-1a, IL-6 and tumour necrosis factor (TNF)-a. 26 A recent, large Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) trial has shown that a PCSK9 inhibitor, canakinumab, reduced the risk of adverse cardiovascular outcomes in patients with a history of myocardial infarction and elevated hsCRP. 28 CANTOS population included individuals with hsCRP levels 2 mg/l, and the beneficial effect of canakinumab was only demonstrated in participants who had a decrease in hsCRP levels <2 mg/l. 28, 29 In the study by Zenti et al, two different PCSK9 inhibitors (evolocumab and alirocumab) had no significant effect on reducing inflammatory markers, including hsCRP, so there is a concern whether their beneficial effect on lipid profile could be translated into reducing adverse cardiovascular events. However, in the present study, PCSK9 inhibitors significantly reduced the proatherogenic Lp(a) levels in most patients, suggesting a favourable effect on cardiovascular outcomes. 22 The combined treatment with lipoprotein apheresis and PCSK9 inhibition has been investigated recently. 30, 31 It was effective in reducing LDL-C and TG levels, while demonstrating mixed results regarding HDL-C concentration. In the current study by Zenti et al., there was a favourable effect on HDL-C level. 22 In addition, a decrease in TG levels achieved with apheresis was maintained with PCSK9 inhibitors, which is a novel finding. These observations suggest that combined treatment with lipoprotein apheresis and PCSK9 inhibitors could achieve a sustained improvement in lipid profile. The present study may be seen as an attempt to provide new directions in lipid management for the prevention of adverse cardiovascular outcomes.
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